Arkolith/Insider Trading/ATHA/Form 4

Renninger Robert

Chief Financial OfficerAthira Pharma, Inc. (ATHA) · full profile →Form 4 · filed Jan 5, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2K
Net Open-Market Flow
-$2K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2026Sell(S)297$6.88$2K13K
Dec 31, 2025Option exercise(M)1K—$013K
Nov 18, 2025Grant(A)1K$2.31$2K12K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 31, 2025Option exercise(M)1K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002037968-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML